Insights

During the 2024 Great Debates & Updates in Hematological Malignancies Meeting, Joseph Mikhael, MD, MEd, FRCPC, FACP, shares expert insight on when to choose CAR-T therapy versus bispecific antibodies in multiple myeloma treatment.

During the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Jessica Altman, MD, argues in favor of using sequential therapy over triplet therapy for patients with newly diagnosed acute myeloid leukemia who are ineligible for...

At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Ashley Rosko, MD, discusses why the comprehensive health of patients with multiple myeloma should be analyzed to make transplant decisions, rather than only focusing on...

At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Yee, MD, speaks about mitigating the risks of infection while using BCMA bispecific antibodies as treatment.

At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, Andrew Yee, MD, discusses whether or not it is suitable for a patient to receive additional BCMA therapy after previous BCMA therapy.

At the 2024 Great Debates & Updates in Hematologic Malignancies meeting, John Allan, MD, shares expert insight on the impact targeted agents have in the treatment of CLL, focusing particularly on frontline therapy.

During the Great Debates & Updates in Hematologic Malignancies meeting, Samuel Yamshon, MD, examines the efficacy of using CAR T-cell therapy to treat elderly patients with relapsed/refractory diffuse large B-cell lymphoma.

During the 2024 Great Debates & Updates in Hematologic Malignancies meeting in New York, Peter Martin, MD, argued in favor of alternative treatment regimens over CAR T-cell therapy for treating follicular lymphoma.

At the 2024 Great Debates & Updates Meeting in Hematological Malignancies in New York, John Allan, MD, discusses if there is a role for chemo-immunotherapy in the CLL treatment landscape.

Joshua Richter, MD, discusses promising novel advances in the multiple myeloma treatment landscape, including the use of T-cell redirection therapy and possible treatment approvals to come.